The recent study by McMaster University researchers, which found consistent evidence that use of hormone replacement therapy (HRT) is associated with breast cancer globally, will only increase physician and patient confusion over efficacy of HRT, as it fails to make the all-important distinction between the types of HRT used by women in the group with higher incidence of breast cancer.
A study to be published in Jan 2012 Journal of Epidemiology and Community Health by McMaster University researchers have found consistent evidence that use of hormone replacement therapy (HRT) is associated with breast cancer globally. This study comes at a time when more women are seeking HRT medication from the doctors to control the symptoms of menopause, such as hot flashes, weight gain and mood swings.
A landmark study published in the American Journal of Obstetrics and Gynecology (AJOG) found women with a short cervix treated with vaginal progesterone showed a decreased rate of preterm birth by 42%, and significantly reduced the rate of respiratory distress syndrome and the need for mechanical ventilation, as well as a composite of several complications of premature newborns (e.g. infection, necrotizing enterocolitis, intracranial hemorrhage, etc.).
Dec. 8 (Bloomberg) -- Pfizer Inc., the world’s largest drugmaker, agreed to settle claims that its menopause drugs caused cancer in three women who won a $72.6 million jury award earlier this week, a lawyer said.
Mylan Inc. (MYL) will receive a license to sell generic versions of Vivelle-Dot, a treatment for menopause symptoms, after settling a patent litigation lawsuit with Novartis AG's (NVS) Novartis Pharmaceuticals Corp. affiliate.
Pursuant to the agreement, pending litigation will be dismissed and Mylan will receive a license to begin selling generic versions of the product on Dec. 16, 2013, or earlier under certain circumstances.